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Introduction
According to data from Taiwan’s Department of
Health, Executive Yuan, cardiovascular disease (CVD)
is the leading cause of death among women in Taiwan,
accounting for more than 10,000 deaths annually,
which exceeds the mortality from breast and cervical
cancer (about 2,200 deaths annually). However, pre-
menopausal women have lower cardiovascular mor-
bidity and mortality than men of a similar age. This is
considered to be attributed to the protective effects of
female ovarian sex hormones. After menopause, how-
ever, such effects are lost and the incidence of CVD
increases; the prevalence of CVD in men and women is
similar during the eighth decade of life [1,2].
Menopause-related estrogen deficiency has been
considered to be associated with an increased risk for
CVD. Estrogen deficiency has metabolic, hemodynamic
and vascular consequences, and affects a number of
CVD risk factors, which contribute to an increase in
CVD risk. As a result, coronary artery diseases (CAD)
along with stroke are the two main contributors of
mortality among postmenopausal women.
Observational studies [3–10] have suggested 
that long-term hormone therapy (HT) expresses an
antiatherogenic profile via mechanisms that include fav-
orable modifications of lipoprotein levels, coagulation–
fibrinolysis and glucose metabolism, decrease in
homocysteine levels, enhancement of vasodilatation,
decrease in the expression of vascular cell adhesion
molecule, and maintenance of endothelial integrity
and function and vascular extracellular matrix homeo-
stasis. In accordance with the aforementioned effects,
observational studies have reported a reduction in
CAD risk ranging from 31–44%. However, the recent
results of two randomized controlled trials (RCTs) that
evaluated the effect of HT on primary (WHI) [11–13]
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SUMMARY
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and secondary (HERS) [14] CVD prevention have
questioned the efficacy of HT, despite confirming 
the lipid-lowering effect of estrogen. However, many
unsettled questions remain regarding the issue of HT
and CVD.
Therefore, this review will further discuss CVD in
postmenopausal women from the perspective of phys-
ical changes, discrepant results between observational
studies and RCTs, and experimental studies, and sum-
marize the unanswered questions regarding HT and
cardiovascular risk. From the discussion, the most
important thing is to find out what is ideally required
for using HT in postmenopausal women.
Menopause-induced Changes in
Cardiovascular Function
In 1976, the Framingham investigators reported a 
2.6-fold higher incidence of cardiovascular events in
age-matched postmenopausal women compared with
premenopausal women [15]. The excess risk of coro-
nary heart disease (CHD) associated with surgical
menopause was 2.7-fold higher compared with pre-
menopausal women of the same age and 2.2-fold
higher compared with women with a natural menopause
[16]. It is plausible that the estrogen deficient state
accounts for changes in the cardiovascular function of
postmenopausal women.
The most frequent cause of CVD is atherosclerosis.
Menopause-related estrogen deficiency has metabolic,
hemodynamic and vascular consequences, and affects
a number of CVD risk factors that are related to the
development of atherosclerosis. Menopause induces
changes towards an atherogenic lipid and lipoprotein
profile. Postmenopausal women have higher serum lev-
els of total cholesterol and low-density lipoprotein
cholesterol and lower serum levels of high-density
lipoprotein cholesterol than their premenopausal
counterparts [17]. In addition, a link between elevated
mean plasma levels of lipoprotein(a) and premature
atherosclerosis, CAD, clinically manifest myocardial
infarction, and stroke has been postulated on the basis
of case-control studies [18–20]. In most epidemio-
logic studies [21,22], a postmenopausal increase in
lipoprotein(a) concentrations has been demonstrated.
The involvement of hemostatic factors, including
coagulation, coagulation inhibitor and fibrinolytic fac-
tors, in thrombogenesis and atherogenesis may also
play a role in the observed variation in cardiovascular
risk according to menopausal status. Some coagu-
lation factors, such as fibrinogen and factor VII, may
play important roles in the pathogenesis of CHD [23].
Population-based studies consistently showed higher
levels of fibrinogen and factor VII in postmenopausal
than in premenopausal women of the same age [24–26].
Congenital deficiencies of the coagulation inhibitors
antithrombin III, protein C and protein S have been
associated with increased risk of venous thrombo-
embolism [27] and CHD [28]. Meade et al [28] sug-
gested that antithrombin III levels may rise as a
compensatory anticoagulant response to increased lev-
els of procoagulant fibrinogen and factor VII; the same
may apply to the increases in protein C and protein S
as coagulation factors increase. Therefore, levels of
antithrombin III, protein C and protein S increase after
menopause [29–33].
Fibrinolytic hypofunction, as evidenced by increased
plasma concentrations of plasminogen activator
inhibitor-1 (PAI-1) and tissue plasminogen activator
(TPA) antigen, is associated with CHD [34,35]. When
compared with premenopausal women, PAI-1 levels 
in postmenopausal women have consistently been
reported to be higher [36,37].
As estrogen receptors have been identified in the
hearts of primates and as both deprivation and replace-
ment of sex hormones can alter ventricular performance
in female animals [38], a direct effect of sex hormone
on myocardial function cannot be excluded. Further-
more, recent reports also demonstrated menopause-
related alteration in left ventricular wall thickness as
well as Doppler indices of left ventricular filling [39].
From the aforementioned data, it seems that with-
drawal of estrogen during menopause is associated
with an increased risk of CVD above that seen for pre-
menopausal women, and this has led to interest in dis-
cussing the beneficial effects of HT in postmenopausal
women.
Difference Between Observational Studies
and RCTs on Cardiovascular Effects
Observational trials of HT
Meta-analysis of epidemiologic data from several
observational trials [3–10] demonstrates that women
using HT after menopause have a significant reduction
in CHD events with overall relative risk ranging from
0.39 to 0.77 (Figure). In addition to reducing CHD
events, cross-sectional data suggested less subclinical
atherosclerosis in HT users [40,41]. The much larger
observational Nurses’ Health Study of 70,000 asymp-
tomatic women demonstrated a lower incidence of
CHD events and all-cause mortality in HT users com-
pared with non-users [8–10]. It should be noted that
most women in the Nurses’ Health Study started HT 
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in the perimenopausal period and were free of known
CHD at the start of the study.
RCTs of HT
Recently, a series of RCTs of HT in both primary and
secondary prevention of CVD have questioned the effi-
cacy of HT [42–47] (Table 1). In investigating inter-
mediate CAD outcome by angiography following HT,
although the study of estrogen in the prevention of
atherosclerosis (EPAT) [44] reported a decrease in
intima-media thickness in the carotid artery of women
using 17β-estradiol, the majority of the RCTs have
reported neither harm nor benefit (Table 1).
RCTs [11–14,48–51] evaluating cardiovascular out-
comes have also failed to confirm any cardiovascular
benefit (Table 2). The Heart and Estrogen/progestin
Replacement Study (HERS) [14] was the first reported
secondary prevention trial in 2,763 women with known
CHD. At a mean of 4.1 years, there was no significant
difference between the HT and placebo groups in the
outcomes of non-fatal myocardial infarction or cardiac
death (hazard ratio, 0.99; 95% confidence interval
[CI], 0.8–1.22). In the first year after randomization,
patients in the HT group had an increased event rate
that decreased steadily in the subsequent years with a
significant trend, although Grady et al (HERS II) [48]
reported lower rates of coronary heart events at 4–5
years among women on HT in HERS, which did not
persist during additional years of follow-up. Similar
results for secondary prevention were also noted in the
Papworth HRT atherosclerosis study (PHASE) [49]
using transdermal 17β-estradiol with or without 
transdermal norethisterone acetate.
The largest RCT is the Women’s Health Initiative
(WHI) [11], which included 16,608 women randomized
to conjugated equine estrogen and medroxyproges-
terone acetate or placebo with a mean 5.2-year follow-
up. Combined HT was associated with a hazard ratio
for CHD of 1.24 (95% CI, 1.00–1.54). The elevation in
risk was most apparent at 1 year (hazard ratio, 1.81;
95% CI, 1.09–3.01). In addition, hysterectomized
women (10,739 subjects) were randomized to either
conjugated equine estrogen or placebo, and followed
for a mean duration of 6.8 years [12]. There was also
no significant difference between HT and placebo
groups, but there was a suggestion of lower CHD risk
with conjugated equine estrogen among women 50–59
years of age at baseline [13].
A common finding of these RCTs of HT is an
apparent increase in cardiovascular events in the HT
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Figure. Summary of observational studies of hormone therapy and cardiovascular disease.
group in the early years of treatment, which appears to
diminish in later years. In addition to the discrepant
results compared to observational trials, most differ-
ences were in the advanced age and late initiation of
therapy in the RCT study populations.
Reasons for Discrepant Results Between
Observational Studies and RCTs
The mean age and timing of HT initiation (peri-
menopause vs. post-menopause) are generally con-
sidered to be the most important factors for the
conflicting results between observational studies and
RCTs and explain why RCTs do not associate HT with
cardioprotection.
The advanced age and timing of HT initiation in
the WHI population [11–13], as well as in other RCTs
[14,48–51], should include women with a high risk for
CHD. These women may lack symptoms of atheroscle-
rosis, but this does not exclude the presence of a
lesion. It results in “healthy users” bias. Therefore, the
results of primary prevention of CHD in the WHI is
quite similar to those of secondary prevention in HERS
[14], which showed an early increase in clinical coronary
events followed by a subsequent decline. Although, as
with other experimental studies [52–58], these studies
confirmed the beneficial effects of estrogen on lipo-
protein metabolism, late initiation of HT allows 
dyslipidemia to contribute to atherosclerosis.
In addition, estrogen induces changes in hemosta-
sis, which may disrupt the cycle of damage and repair
in the arterial endothelium. However, there was a lack
of experimental data to show the changes in coagula-
tional, anticoagulational, and fibrinolytic factors in
patients in HERS, WHI, and observational studies.
According to several experimental studies of the effects
of HT on hemostatic factors, it is worth noting that
there was a steady trend toward fibrinolysis: reduced
PAI-1 and TPA antigen mostly occurred after 1 year of
HT and adverse effects of HT on antithrombin III and
protein C subsided after 12 months of HT [56–61].
These studies provide evidence supporting an increased
risk of venous thromboembolism in the first year of
HT. A common finding of HERS and WHI is an appar-
ent increase in cardiovascular events in the HT groups
in the early years of treatment, which appears to
diminish in later years. One possible explanation for
this observation is the aforementioned changes in
hemostatic factors, which would increase the risk of
thrombogenesis on commencement of therapy, but
the risk would be transient, leading to beneficial effects
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Table 1. Summary of randomized controlled trials of hormone therapy by evaluating intermediate coronary artery disease
outcomes
Study Age of subjects, yr Regimens Effect
ERA [43] 65.8 CEE/CEE + MPA ↔
PHOREA [44] 17β-E2 + gestodene ↔
EPAT [45] 62.2 17β-E2 +
HERS B-Mode substudy [46] 67.0 CEE + MPA ↔
WAVE [47] 65.0 CEE/CEE + MPA ↔
WELL-HART [48] 63.5 17β-E2/17β-E2 + MPA ↔
CEE = conjugated equine estrogen; MPA = medroxyprogesterone acetate; 17b-E2 = 17b-estradiol.
Table 2. Summary of randomized controlled trials of hormone therapy on cardiovascular disease outcomes
Age, yr Regimen Effect Early events
Primary prevention studies
WHI [12] 63.3 CEE + MPA ↑ ↑
WHI update [14] 63.3 CEE + MPA ↔ ↑
WHI [13] 63.6 CEE ↔ ↔
Secondary prevention studies
HERS [15,49] 66.7 CEE + MPA ↔ ↑
PHASE [50] 66.5 Transdermal E2 + NETA ↔
ESPRIT [51] 62.6 E2 ↔
WHISP [52] > 55 17β-E2 + NETA ? ↔
CEE = conjugated equine estrogen; MPA = medroxyprogesterone acetate; E2 = estradiol; NETA = norethisterone acetate.
as fibrinolytic and coagulational factors return into
balance.
Another factor that should also be considered is
that estrogen receptor expression differs in normal and
atherosclerotic arteries. Miller et al [62] reported that
in vitro platelet–endothelial interactions are influenced by
estrogen. They suggested that despite decreased adhe-
sion properties at low shear when platelets were incu-
bated with estrogen, once platelet adhesion occurred,
such as easily noted in injured vessels, the process of
aggregation may be more easily induced in vivo. In addi-
tion, the estrogen levels in postmenopausal women
with diseased coronary vessels are decreased, and 
this may also compromise endothelial response to HT.
These experimental findings may explain the lack of a
cardioprotective effect of HT in RCTs.
Conclusion
The WHI [11–13] as well as other RCTs have had a
tremendous impact on both the public and on clini-
cians. Although they have provided information on the
benefits and risks associated with HT, they have not
actually demonstrated the effects of HT on cardiovas-
cular risk. Serious questions remain regarding the choice
of HT preparations, different estrogen and progestin
combinations and doses and, more importantly, the
age and physical conditions at which women are
exposed to these agents. In addition, a cluster of fac-
tors are responsible for the genesis and progression of
CVD. Therefore, at present, there is insufficient evidence
to justify using HT solely for CVD in postmenopausal
women. Until we further evaluate their specific actions
and how these different factors interact, the issue related
to HT and cardiovascular risk will remain unsettled.
However, from these studies, it should be noted that
HT use should be individualized after evaluating the
condition of each postmenopausal patient. Ideally,
different preparations and dosages of HT in post-
menopausal women who are at risk of CVD, before
atheromatous lesions have developed, should be
investigated.
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